Alexion receives orphan drug designation for Soliris in Europe
The European Commission has granted orphan drug designation to Alexion Pharmaceuticals’ Soliris (eculizumab), a terminal complement inhibitor, to treat patients with myasthenia gravis (MG).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Myasthenia Gravis | Pharmaceuticals